Small study hints anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients By Brenda Goodman , CNN 11 minute read ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

GE HealthCare Technologies Inc. GEHC has received the FDA’s approval for an updated label for its positron emission ...

Small study hints anti-amyloid therapy may keep Alzheimer’s symptoms at ... The researchers have been testing amyloid-removing therapies in a group of people who have rare genetic mutations that ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

GE HealthCare (GEHC) announced that the U.S. Food and Drug Administration has approved an updated label for its positron emission tomography or PET imaging agent Vizamyl (flutemetamol F 18 injection) ...

Moving Beyond Anti-amyloid Therapy for the Prevention and Treatment of Alzheimer's Disease. Michael A Castello; John David Jeppson; Salvador Soriano. Disclosures. BMC Neurol. 2014;14(169) ...

Voyager Therapeutics presents data on tau silencing therapy VY1706 and anti-amyloid therapy at ASGCT 2025. Quiver AI Summary. Voyager Therapeutics, Inc. has announced that it will present eight ...